Identification of Prognostic lncRNA Related to the Immune Microenvironment of Soft Tissue Sarcoma

Table 4

Univariate Cox analysis of clinicopathological factors in patients with OS-related soft tissue sarcoma.

ID	HR	HR.95L	HR.95H	value
Risk	2.819425565	1.844548576	4.30954252	1.68-06
Age	1.020203157	1.004851698	1.035789145	0.009720255
Type 1	0.822698599	0.499921639	1.353878154	0.442550772
Type 2	0.674303076	0.359714697	1.264014624	0.219006691
Type 3	0.895366536	0.477370431	1.679369275	0.730530813
Metastasis	3.013737497	1.833539793	4.953595082	1.35-05
Race 1	1.085399289	0.132018532	8.923683664	0.939229846
Race 2	0.791066954	0.108401374	5.772868961	0.817221062
Postoperative_radiotherapy	0.988244054	0.618585136	1.578806623	0.960542537
Margin	2.553571993	1.667915977	3.909507441	1.60-05
Sex	0.854557794	0.571819232	1.277097695	0.443231109
Tumor tissue site 1	1.222885503	0.726840069	2.057466308	0.448437108
Tumor tissue site 2	1.224341377	0.756895753	1.980473268	0.409450534

Type 1: dedifferentiated liposarcoma; type 2: leiomyosarcoma; type 3: undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma/high-grade spindle cell sarcoma; race 1: black; race 2: white; tumor tissue site 1: extremity; tumor tissue site 2: retroperitoneum/upper abdominal; OS: overall survival; HR: hazard ratio.